Cover Image
市場調查報告書

乳癌疫苗全球市場與臨床研發線未來展望

Global Breast Cancer Vaccine Market & Clinical Pipeline Outlook 2022

出版商 KuicK Research 商品編碼 408668
出版日期 內容資訊 英文 190 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
乳癌疫苗全球市場與臨床研發線未來展望 Global Breast Cancer Vaccine Market & Clinical Pipeline Outlook 2022
出版日期: 2016年12月14日 內容資訊: 英文 190 Pages
簡介

本報針對全球各國乳癌疫苗研發線製品開發、治療狀況分析、提供乳癌疫苗作用排序、患者數量動向預測、現在治療情況與今後預測、治療主要促進、控制因素、主要研發線製品現在治療狀況、各階段需要克服的課題、企業分類動向預測調查、考察。

第1章 什麼是癌症疫苗?

第2章 癌症疫苗作用排序

  • 遺傳性型癌症疫苗作用排序
  • 細胞系癌症疫苗作用排序
  • 神經節甘脂抗原型的癌症疫苗作用排序
  • 勝□癌症疫苗作用排序
  • 腫瘍宿主關係癌症疫苗作用排序

第3章 乳癌疫苗作用排序

  • 引起免疫系統的基本策略
    • 克服免疫控制
    • 免疫檢視重點調整
  • 免疫原性與治療藥反應
  • 乳癌治療用疫苗

第4章 全球乳癌數量

  • 美國
  • 歐洲
  • 亞洲
  • 其他國家 (RoW)

第5章 全球乳癌疫苗市場:現在情形

  • 未開拓的市場機會
  • 全球乳癌疫苗:研發線概要

第6章 個分類化乳癌疫苗需求

第7章 全球乳癌疫苗市場動態

  • 良好的市場指標
  • 實行的課題

第8章 全球乳癌疫苗市場未來展望

第9章 乳癌疫苗開發、販售期關FDA指南

  • 治療初期、後期需考慮事項
    • 患者人口
    • 免疫反應觀察
    • 以效能證明的生物標記
    • 刺激免疫反應的佐劑
    • 多抗原疫苗
    • 癌症疫苗投藥、即時或短期病狀的進行、再發生
    • 併用療法、附隨療法
  • 治療初期考慮事項
    • 開始投藥與開始投藥行程
    • 加速、維持療法
    • 投藥數量增加
    • 初期單一群/亂數型第II期治療
  • 治療後期考慮事項
    • 治療初期安全性檔案
    • 終點
    • 統計問題
    • 管理課題
    • 遲效性疫苗硬化
    • 自製疫苗的治療
    • 認證規範的加速化

第10章 全球乳癌疫苗治療研發線:企業分類、期數分類

  • 臨床前
  • 第I期
  • 第I/II期
  • 第II期
  • 第II/III期
  • 第III期

第11章 乳癌疫苗被中斷、延期的治療研發線:企業分類、期數分類

  • 延期
  • 無報告
  • 中斷

第12章 競爭環境

  • Advaxis
  • AlphaVax
  • AVAX Technologies
  • Dendreon Corporation
  • Galena Biopharma
  • Generex Biotechnology
  • GlaxoSmithKline
  • Immune Design
  • Imugene
  • Immunovative Therapies
  • Immunovaccine
  • Inovio Pharmaceuticals
  • Merck
  • NewLink Genetics
  • Recombio
  • TapImmune
  • ViroMed

圖表一覽

目錄

“Global Breast Cancer Vaccine Market & Clinical Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global breast cancer vaccine development market. Currently there is no single breast cancer vaccine commercially available in the market. This report analyzes the ongoing clinical trial of 36 breast cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the vaccine. Most of the breast cancer vaccines in clinical trials are in preclinical phase followed by Phase-I trials. The advance stage of development of breast cancer vaccine in clinical trials across the globe is in Phase-III.

The conventional cancer treatment methods have proved their importance in last decade. They are widely accepted among patients and physicians (oncologists) because of familiarity and large amount of statistically significant data supporting their efficacy. Despite their benefits, they sometimes fall short in meeting the patient's personal requirements. For instance, efficacy is a major requirement, but different patients display different response to the same medication, this is attributed to their unique genetic makeup. To meet the individual's necessities, high efficacy and safety, concept of cancer vaccine was formulated.

The best part with cancer vaccines is that they are capable of inducing “memory effect” in the immune cells. As a result, even in the absence of cancer vaccine molecule in the body, immune cells maintain their ability to search and destroy cancer cells. These memory effects are engraved on lymphocytes which keep on producing antigen long after the introduction of the initiator molecule. Pharmaceuticals companies are investing heavily in R&D segment to discover more properties of cancer vaccines. The benefits offered by cancer vaccine have poised the market to increase several folds.

At present the breast cancer vaccines are in emerging stages and this market has yet to be tapped by pharmaceutical companies. They are diverging funds towards research and development segment for advances in innovative breast cancer vaccines which will generate large amount of revenues. In recent years significant progress has been made on technological and scientific levels but still no vaccine for the treatment of breast cancer has seen market introduction in any part of the globe.

The present therapeutics available in market for breast cancer shows modest results in majority of patients which offers unexplored marketing opportunities for better innovative products to enter in competition. It is expected that more oncologists will prescribe the innovative breast cancer vaccines to their patients due to greater therapeutic effects. The higher rates of prescription would lead to high degree of market penetration and increased market share. The revenues generated in this way will encourage the pharmaceutical companies to fund new projects for the development of better breast cancer vaccines.

The first commercially available breast cancer vaccine is expected to be available in the market in next 5-7 years. Clinical trials would be able to come with thoroughly checked version of products under investigation which would be able to provide higher levels of medical care to breast cancer patients. Most of the innovative products are at the advance stages of clinical trials which are supposed to clear the targeted end points. Market introduction of these new products are supposed to generate significant revenues for the pharmaceutical companies in coming years.

Table of Contents

1. What are Cancer Vaccines?

2. Mechanism of Cancer Vaccines

  • 2.1. Idiotype Cancer Vaccine Mechanism
  • 2.2. Cellular Cancer Vaccines Mechanism
  • 2.3. Ganglioside Antigens based Cancer Vaccines Mechanism
  • 2.4. Peptide Cancer Vaccine Mechanism
  • 2.5. Tumor Host Interaction Cancer Vaccine Mechanism

3. Mechanism of Breast Cancer Vaccine

  • 3.1. Principle Strategies for Eliciting Immune System
    • 3.1.1. Overcoming Immune Suppression
    • 3.1.2. Modulation of Immune Checkpoints
  • 3.2. Immunogenicity & Responses to Therapies
  • 3.3. Breast Cancer Therapeutic Vaccines

4. Global Breast Cancer Incidence

  • 4.1. US
  • 4.2. Europe
  • 4.3. Asia
  • 4.4. Rest of the World

5. Global Breast Cancer Vaccine Market Current Scenario

  • 5.1. Unexplored Opportunity
  • 5.2. Global Breast Cancer Vaccine Pipeline Overview

6. Need for Personalized Breast Cancer Vaccines

7. Global Breast Cancer Vaccine Market Dynamics

  • 7.1. Favorable Parameters
  • 7.2. Commercialization Challenges

8. Global Breast Cancer Vaccine Market Future Prospects

9. FDA Guideline for the Development & Marketing of Cancer Vaccines

  • 9.1. Considerations for Both Early and Late Phase Clinical Trials
    • 9.1.1. Patient Population
    • 9.1.2. Monitoring The Immune Response
    • 9.1.3. Biomarkers As Evidence Of Efficacy
    • 9.1.4. Adjuvants Used To Stimulate Immune Response
    • 9.1.5. Multi-Antigen Vaccines
    • 9.1.6. Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
    • 9.1.7. Concomitant And Subsequent Therapies
  • 9.2. Considerations for Early Phase Clinical Trials
    • 9.2.1. Starting Dose And Dosing Schedule
    • 9.2.2. Booster And Maintenance Therapy
    • 9.2.3. Dose Escalation
    • 9.2.4. Single-Arm Versus Randomized Phase 2 Trials In Early Development
  • 9.3. Considerations For Late Phase Clinical Trials
    • 9.3.1. Safety Profile From Early Phase Clinical Trials
    • 9.3.2. Endpoints
    • 9.3.3. Statistical Issues
    • 9.3.4. Control Issues
    • 9.3.5. Delayed Vaccine Effect
    • 9.3.6. Autologous Vaccine Trials
    • 9.3.7. Accelerated Approval Regulations

10. Global Breast Cancer Vaccine Clinical Pipeline by Company & Phase

  • 10.1. Preclinical
  • 10.2. Phase-I
  • 10.3. Phase-I/II
  • 10.4. Phase-II
  • 10.5. Phase-II/III
  • 10.6. Phase-III

11. Discontinued & Suspended Breast Cancer Vaccine in Clinical Pipeline by Company & Phase

  • 11.1. Suspended
  • 11.2. No Development Reported
  • 11.3. Discontinued

12. Competitive Landscape

  • 12.1. Advaxis
  • 12.2. AlphaVax
  • 12.3. AVAX Technologies
  • 12.4. Dendreon Corporation
  • 12.5. Galena Biopharma
  • 12.6. Generex Biotechnology
  • 12.7. GlaxoSmithKline
  • 12.8. Immune Design
  • 12.9. Imugene
  • 12.10. Immunovative Therapies
  • 12.11. Immunovaccine
  • 12.12. Inovio Pharmaceuticals
  • 12.13. Merck
  • 12.14. NewLink Genetics
  • 12.15. Recombio
  • 12.16. TapImmune
  • 12.17. ViroMed

List of Figures

  • Figure 1-1: Categorization & Function of Cancer Vaccines
  • Figure 2-1: Classification of Different Types of Cancer vaccines
  • Figure 3-1: Development of a Cellular Immune Response against TAA
  • Figure 4-1: US -Number of New Cases & Deaths of Breast Cancer, 2016
  • Figure 5-1: Global Breast Cancer Vaccine Pipeline by Phase (%), 2016 till 2022
  • Figure 5-2: Global Breast Cancer Vaccine Pipeline by Phase (Numbers), 2016 till 2022
  • Figure 5-3: Global Breast Cancer Vaccine Pipeline by Phase (%), 2016 till 2022
  • Figure 5-4: Global Breast Cancer Vaccine Pipeline by Phase (Numbers), 2016 till 2022
  • Figure 6-1: Overview of Personalized Cancer Vaccines Development
  • Figure 6-2: Methodology for the Development of Personalized Cancer Vaccine
  • Figure 6-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
  • Figure 7-1: Favorable Parameters for Breast Cancer Vaccine Development
  • Figure 7-2: Challenges for Breast Cancer Vaccine Market
  • Figure 12-1: Advaxis Clinical Pipeline
  • Figure 12-2: AlphaVax Clinical Pipeline Overview
  • Figure 12-3: Galena Biopharma Clinical Pipeline Overview
  • Figure 12-4: Generex Biotechnology Clinical Pipeline Overview
  • Figure 12-5: Immune Design Clinical Pipeline Overview
  • Figure 12-6: Imugene Clinical Pipeline Overview
  • Figure 12-7: Immunovaccine Clinical Pipeline Overview
  • Figure 12-8: Inovio Pharmaceuticals Clinical Pipeline
  • Figure 12-9: NewLink Genetics Corporation Clinical Pipeline
  • Figure 12-10: TapImmune Clinical Pipeline Overview
  • Figure 12-11: ViroMed Clinical Pipeline Overview
Back to Top